About 7 results found for searched term "IMT1" (0.134 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2034 | Pemetrexed disodium | Antifolate |
| Alimta, LY231514 disodium | ||
| Pemetrexed is a novel antifolic acid antimetabolic compound with K I of 1.3 nM, 7.2 nM, and 65 nM for TS, DHFR, and GARFT, respectively. | ||
| M11519 | IMT1 | Mitochondrial Related |
| IMT1 is the first, specific and non-competitive inhibitor of human mitochondrial RNA polymerase (POLRMT). IMT1 induces conformational changes in POLRMT that block substrate binding and transcription in a dose-dependent manner in vitro. IMT1 reduced deoxynucleoside triphosphate levels and citric acid cycle intermediates, resulting in significant depletion of cellular amino acid levels. | ||
| M13368 | IMT1B | DNA/RNA Synthesis |
| LDC203974 | ||
| IMT1B (LDC203974) is a highly specific human mitochondrial RNA polymerase (POLRMT) inhibitor that inhibits mitochondrial DNA (mtDNA) expression. IMT1B has antitumor effects. | ||
| M20417 | Flibanserin | 5-HT Receptor |
| BIMT-17, BIMT-17-BS | ||
| Flibanserin is a nonhormonal, centrally acting molecule that acts as an agonist at postsynaptic 5-HT1A receptors and as an antagonist at 5-HT2A receptors. | ||
| M21491 | Rimtuzalcap | Potassium Channel |
| CAD-1883 | ||
| Rimtuzalcap (CAD-1883) is the first (first-in-class), selective small conductance calcium-activated potassium channel (SK channel) positive allosteric regulator. Rimtuzalcap can be used in the study of movement disorders including essential tremor (ET) and spinocerebellar ataxia (SCA). | ||
| M25107 | Fidasimtamab | EGFR/HER2 |
| IBI-315; BH2950 | ||
| Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity. | ||
| M25188 | Rimteravimab | Anti-infection |
| XVR011 | ||
| Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
